文献速递前列腺癌

雄激素剥夺治疗应答持续时间对mCRPC患者接受恩杂鲁胺或阿比特龙治疗的预后作用

Prognostic role of the duration of response to androgen deprivation therapy in patients with metastatic castration resistant prostate cancer treated with enzalutamide or abiraterone acetate.
PubMed 文献 · Prostate Cancer Prostatic Dis · 2021-02-18

该回顾性研究评估了转移性去势抵抗性前列腺癌(mCRPC)患者接受恩杂鲁胺或阿比特龙治疗时,既往雄激素剥夺治疗(ADT)应答持续时间的预后价值。255例患者按ADT应答时间分为<12个月、12-36个月和>36个月三组,结果显示ADT应答越长,无进展生存期和总生存期越好,且在多西他赛未治和经治患者中均有此趋势。结论认为ADT应答持续时间是独立的预后因素。

要点

  • ADT应答>36个月者OS和PFS显著优于<12个月者(HR 0.41)。
  • 多西他赛未治患者中ADT应答>36个月者PFS达20个月。
  • 多西他赛经治患者中ADT应答>36个月者OS达21.4个月。

核心结论

  • ADT应答持续时间是mCRPC患者接受阿比特龙或恩杂鲁胺治疗的独立预后因素。

研究设计与样本

  • 回顾性研究,纳入311例接受阿比特龙或恩杂鲁胺治疗的mCRPC患者,其中255例(82%)有ADT起始和持续时间数据。
  • 按ADT应答时间分为三组:G1(<12个月)、G2(12-36个月)、G3(>36个月)。
  • 结局指标为无进展生存期(PFS)和总生存期(OS)。

主要发现

  • 总人群OS中位数:G1 17.3个月,G2 19.9个月,G3 31.6个月(HR G3 vs G1 0.41,95%CI 0.25-0.64;p=0.001)。
  • 多西他赛未治患者OS中位数:G1 18.8个月,G2 35.2个月,G3未达到(HR G3 vs G1 0.33,95%CI 0.14-0.78;p=0.038)。
  • 多西他赛未治患者PFS中位数:G1 7个月,G2 9.3个月,G3 20个月(HR G3 vs G1 0.31,95%CI 0.15-0.62;p=0.003)。
  • 多西他赛经治患者OS中位数:G1 13.1个月,G2 17.2个月,G3 21.4个月(HR G3 vs G1 0.52,95%CI 0.29-0.94;p=0.082)。

关键数值与推荐

  • ADT应答分组界值:<12个月、12-36个月、>36个月。
  • 总人群OS的HR G3 vs G1为0.41(95%CI 0.25-0.64;p=0.001)。

临床怎么用

  • 对于mCRPC患者,启动阿比特龙或恩杂鲁胺治疗前可参考既往ADT应答持续时间进行预后分层。
  • ADT应答持续时间短(<12个月)的患者可能预后较差,需更密切监测。

局限性

  • 回顾性研究设计。
  • 仅255/311例(82%)患者有ADT应答数据,可能存在选择偏倚。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Our retrospective study aims to evaluate the prognostic role of duration of response to androgen deprivation therapy (ADT) in metastatic castration resistant prostate cancer (mCRPC) patients treated with enzalutamide (E) or abiraterone acetate (AA). MATERIALS AND METHODS: Data about ADT start and duration were available in 255 (82%) of 311 patients treated with AA or E. Patients were divided in three groups according to ADT response (group 1 [G1]: <12 months; group 2 [G2]: 12-36 months; group 3 [G3]: >36 months). Outcome measures were progression-free survival (PFS) and overall survival (OS). RESULTS: Patients with longer ADT response had better OS (median 17.3 months G1, 19.9 months G2, 31.6 months G3; HR G3 vs G1 0.41, 95% CI 0.25-0.64; p = 0.001) and better PFS (median 5.9 months G1, 8.8 months G2, 11.7 months G3; HR G3 vs G1 0.41, 95% CI 0.41-0.27; p < 0001). In docetaxel-naive patients, median OS was 18.8 in G1, 35.2 in G2, and not reached in G3 (HR G3 vs G1 0.33, 95% CI 0.14-0.78; p = 0.038), median PFS was 7 months G1, 9.3 months G2, and 20 months G3 (HR G3 vs G1 0.31, 95% CI 0.15-0.62; p = 0.003). In postdocetaxel patients, median OS was 13.1 months in G1, 17.2 months in G2, and 21.4 months in G3 (HR G3 vs G1 0.52, 95% CI 0.29-0.94; p = 0.082), while median PFS was 5.2 months in G1, 6.8 months in G2, and 8.3 months in G3 (HR G3 vs G1 0.54, 95% CI 0.32-0.91; p = 0.067). CONCLUSIONS: Duration of ADT response is an independent prognostic factor of outcome with AA or E.

来源:Prostate Cancer Prostatic Dis,查看原文。版权归原作者所有。

引用

  1. Di Stefano RF, Tucci M, Turco F, et al. Prognostic role of the duration of response to androgen deprivation therapy in patients with metastatic castration resistant prostate cancer treated with enzalutamide or abiraterone acetate. Prostate Cancer Prostatic Dis. 2021. PMID: 33603237. doi:10.1038/s41391-021-00336-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。